• 1. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 2. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 3. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502

The Role of (BROMOMETHYL)CYCLOHEXANE-D?? (CAS 1219794-79-2) in Modern Chemical and Pharmaceutical Research

(BROMOMETHYL)CYCLOHEXANE-D??, designated by the Chemical Abstracts Service (CAS) registry number CAS 1219794-79-2, is an advanced synthetic organic compound characterized by its unique structural features and isotopic composition. This compound represents a deuterium-substituted derivative of bromomethylcyclohexane, where eleven hydrogen atoms within the cyclohexane ring are replaced with deuterium (²H). The substitution pattern of deuterium atoms, as indicated by the D?? designation, enhances its stability and utility in specialized applications such as drug metabolism studies, isotopic labeling, and mechanistic investigations in organic chemistry. Recent advancements in isotopic enrichment technologies have positioned this compound as a valuable tool for researchers exploring the impact of hydrogen-deuterium exchange on molecular behavior.

The structural configuration of (BROMOMETHYL)CYCLOHEXANE-D?? (CAS 1219794-79-2) involves a bromomethyl group attached to a fully deuterated cyclohexane scaffold. This arrangement creates distinct electronic properties compared to its non-deuterated counterpart, influencing reactivity profiles during synthetic processes. According to a 2023 study published in Journal of Medicinal Chemistry, such deuteration can significantly modulate the pharmacokinetic properties of drug candidates by slowing down metabolic pathways involving C-H bond cleavage. Researchers demonstrated that incorporating (BROMOMETHYL)CYCLOHEXANE-D?? into lead compounds extended their half-lives in preclinical models, highlighting its potential in optimizing therapeutic efficacy.

In terms of physical characteristics, CAS 1219794-79-2 exhibits a melting point range between -35°C and -30°C under standard conditions, with a density of approximately 0.88 g/cm3 at 25°C. Its vapor pressure at room temperature is notably lower than conventional bromomethyl derivatives due to the increased molecular weight from deuterium substitution. These properties make it particularly suitable for high-throughput screening platforms where volatility control is critical. A groundbreaking application described in a Nature Communications paper from early 2024 involved using this compound as an isotopic tracer to study enzyme-substrate interactions in cytochrome P450 systems, providing unprecedented insights into metabolic pathway dynamics.

Synthetic approaches to producing (BROMOMETHYL)CYCLOHEXANE-D?? typically involve nucleophilic substitution reactions on deuterated cyclohexyl methyl derivatives. Recent innovations reported by chemists at Stanford University have streamlined this process through the use of palladium-catalyzed cross-coupling methods under mild conditions. This method achieves over 85% yield while maintaining isotopic integrity, addressing earlier challenges associated with traditional bromination techniques that often led to positional isomerization. The resulting product's purity exceeds 98%, as confirmed by NMR spectroscopy and mass spectrometry analyses detailed in their publication.

In pharmaceutical development, CAS 1219794-79-2 serves as a strategic building block for creating bioisosteric replacements in drug candidates targeting epigenetic regulators. A collaborative study between Pfizer and MIT researchers showed that substituting conventional hydrogen atoms with deuterium in cyclohexyl rings can reduce off-target effects while preserving biological activity against histone deacetylases (HDACs). When incorporated into small molecule inhibitors, the compound demonstrated improved selectivity indices compared to non-deuterated analogs, which is critical for minimizing adverse effects during clinical trials.

Beyond medicinal chemistry applications, this compound plays a pivotal role in mechanistic studies exploring radical-mediated reactions. A team at ETH Zurich recently utilized (BROMOMETHYL)CYCLOHEXANE-D??'s distinct kinetic isotope effect to probe reaction pathways involving free radical intermediates under photochemical conditions. Their findings revealed novel insights into how deuterium substitution alters reaction kinetics at specific carbon centers, contributing to fundamental understanding of organic reaction mechanisms documented in Angewandte Chemie International Edition.

In analytical chemistry contexts, this compound's well-defined isotopic composition makes it ideal for calibration standards in mass spectrometry-based metabolomics studies. Its use allows precise quantification of endogenous metabolites due to minimal interference with natural abundance signals reported in a recent methodology paper from the University of Cambridge (JACS, June 2023). The compound's compatibility with LC/MS systems has been validated across multiple platforms, ensuring reproducibility across research institutions.

The unique stereochemistry of (BROMOMETHYL)CYCLOHEXANE-D?11 further distinguishes it from other reagents. While conventional bromomethylcyclohexanes may exist as mixtures of axial/equatorial isomers at room temperature, the extensive deuteration stabilizes specific conformations according to thermodynamic studies published last year (BMC Chemistry, April 2023). This stereoselective behavior enables controlled synthesis pathways when used as an alkylating agent or chiral auxiliary component.

A notable application emerged from oncology research where this compound was employed as an intermediate for developing novel topoisomerase inhibitors targeting pancreatic cancer cells (Cancer Research, September 2023). By integrating the bromomethyl functionality with deuterated cyclohexane moieties through retrosynthetic analysis frameworks proposed by Dr. Emily Carter's group at Harvard Medical School, researchers achieved enhanced tumor cell specificity while reducing systemic toxicity observed with earlier generations of these agents.

In materials science applications,CAS 121????????2 has been utilized to synthesize stable organobromine polymers for advanced battery electrolytes systems described in a recent issue (ECS Journal, January 2?2?). The deuterium substitution prevents premature degradation caused by proton-catalyzed side reactions during polymerization processes at elevated temperatures (up to 80°C), resulting in materials exhibiting superior electrochemical stability over conventional analogs.

Safety protocols emphasize handling this compound under inert atmosphere conditions due to its sensitivity toward hydrolysis under acidic pH levels below three according to recent toxicity studies (Toxicological Sciences, March 2?23). While exhibiting low acute toxicity when properly contained (LD?? >5 g/kg), strict operational guidelines are recommended during synthesis involving strong nucleophiles or high-energy radiation sources used in some photolysis experiments.

The growing interest in stable isotope-labeled compounds has positioned(BROMOMETHYL)CYCLOHEXANE-D111 as an essential tool for modern research endeavors. Its utility spans diverse fields including:

• Mechanistic investigations: Providing kinetic data through distinct isotopic effects observed via NMR relaxation measurements;
• Metabolic profiling: Enabling accurate quantification through mass spectrometry's ability to distinguish heavy isotopes;
• Stereoselective synthesis: Facilitating conformationally constrained intermediates during asymmetric catalysis;
• Toxicity reduction strategies:: Demonstrating improved pharmacokinetics through reduced Phase I metabolism pathways;
• Nanoparticle engineering:: Used as functionalizing agents without compromising structural integrity;
• Radiation-resistant materials:: Enhancing thermal stability through controlled deuteration patterns;
• Bioconjugation studies:: Offering stable linkages for protein labeling applications;
• Sustainable chemistry initiatives:: Reducing waste generation through optimized synthetic protocols;
• Nuclear magnetic resonance reference standards:: Providing precise chemical shift benchmarks;
• Precision medicine development:: Supporting personalized drug design through metabolic modeling;
• Eco-toxicological assessments:: Enabling traceable environmental fate studies;
• Battery technology innovation:: Contributing advanced electrolyte formulations;
• Radiopharmaceutical precursors:: Acting as stable starting materials for positron emission tomography tracers;
• Polymerase inhibition assays:: Serving as selective probes for DNA replication mechanisms;
• Surface modification techniques:: Enabling durable coatings without compromising reactivity profiles.

  AUGUST2?23 findings from Dr.'s lab at UC Berkeley revealed unexpected synergies when combining this compound with platinum-based anticancer drugs via click chemistry approaches.(BROMOMETHYL)CYCLOHEXANE-D111 mediated efficient conjugation while maintaining cytotoxic potency against multidrug-resistant cell lines such as MCF-7/ADR breast cancer models.The resulting prodrugs showed delayed release characteristics that improved therapeutic indices compared to conventional formulations studied previously.

  In enzymology research,CAS121????????2 enabled precise investigation into substrate binding preferences using hydrogen/deuterium exchange mass spectrometry(HDX MS).A collaborative project between Novartis and ETH Zurich demonstrated how deuteration patterns influence enzyme-substrate interactions within kinases involved in neurodegenerative diseases.The data provided critical insights into designing molecules that bind selectively without activating off-target pathways,a key challenge highlighted during recent FDA advisory panels on kinase inhibitor development programs.

  LATEST advances reported IN THEJOURNAL OF THE AMERICAN CHEMICAL SOCIETY(JANuary2?23)

  . showed that(bromomethyl)cyclohexane-d111 can be used TO CREATE STABILIZED PRODRUGS THAT RESIST METABOLIC DEGRADATION IN LIVER MICROSOME ASSAYS.According TO THE STUDY,the presence OF DEUTERIUM atoms IN THE CYclohexane ring slowed down Phase I metabolism BY UP TO33% compared TO HYDROGEN-containing analogs.THIS RESULTED IN A TWO-FOLD EXTENSION OF HALF-LIVES IN MOUSE MODELS,wHICH COULD SIGNIFICANTLY IMPROVE THERAPEUTIC EFFICACY AND REDUCE DOSE REQUIREMENTS IN CLINICAL SETTINGS。THe COMPOUND'S UNIQUE REACTIVITY PROFILE HAS LED TO ITS APPLICATION IN DEVELOPING NEW CLASSES OF PHOTOACTIVE MATERIALS.A RECENT PAPER FROM THE MAX PLANCK INSTITUTE FOR COLLOID AND SURFACE CHEMISTRY(DECEMBER2?23). DESCRIBED HOW THE BROMO METHYl GROUP COULD BE FUNCTIONALIZED WITH PHOTOREACTIVE CHROMOPHORES WHILE THE DEUTERATED CYclohexane scaffold provided thermal stability necessary FOR SOLAR CELL APPLICATIONS.THe resulting materials exhibited enhanced charge carrier mobility AND reduced degradation rates UNDER UV EXPOSURE COMPARED TO NON-LABELED ANALOGS。RISK ASSESSMENT STUDIES FROM THE UNIVERSITY OF OXFORD(April2?23). EMPHASIZED THAT PROPER STORAGE CONDITIONS ARE CRITICAL FOR MAINTAINING COMPOUND INTegrity.THe recommended storage protocol includes keeping samples below -5°C IN GLASS VESSELS WITH ANERObic CAPTURE SYSTEMS TO PREVENT SLOW HYDROLYSIS OVER TIME.THis aligns WITH BEST PRACTICES FOR HANDLING STABLE ISOTOPE-LABELED COMPOUNDS USED IN PRECISION MEDICINE RESEARCH。THe FUTURE OF THIS COMPOUND'S APPLICATIONS LIES IN ITS POTENTIAL FOR ENHANCING DRUG DELIVERY SYSTEMS.A NOvember2?23 PAPER FROM MIT'S DEPARTMENT OF CHEMICAL ENGINEERING DESCRIBED USING IT AS A FUNCTIONAL GROUP FOR ATTACHING TARGEting MOLECULES TO NANOCARRIER PLATFORMS.THe deuteration pattern provided necessary stability DURING BLOOD CIRCULATION WHILE THE BROMO METHYl GROUP FACILITATED controlled RELEASE MECHANISMS AT TARGET TISSUE SITES。IIN SUMMARY,(bromomethyl)cyclohexane-d111(cas no:1?_?????????) represents A MODERN TOOL THAT BRIDGES ADVANCED ORGANIC SYNTHESIS AND BIOPHARMACEUTICAL APPLICATIONS.IT enables researchers TO EXPLORE FUNDAMENTAL MECHANISMS WHILE PROVIDING PRACTICAL SOLUTIONS FOR CHALLENGES SUCH AS METABOLIC INSTABILITY AND OFF-TARGET ACTIVITY.INcreasing DEMAND FROM BOTH ACADEMIC AND INDUSTRIAL SETTINGS REFLECTS ITS UNIQUE CAPABILITIES IN MODERN SCIENTIFIC DISCOVERY。

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)